Mdxhealth presented late-breaking data from the University of Oxford–led GPS-ProMPT study involving 409 localized or locally advanced prostate cancer patients, managed by active surveillance, radical prostatectomy or radiotherapy, with a median follow-up of six years. The presentation at the 41st Annual European Association of Urology Congress highlighted the assay’s prognostic performance across multiple treatment settings.

The GPS mdx test stratified treatment failure risk, delivering 92% six-year freedom-from-failure in active surveillance discordant patients and up to 100% in surgery or radiotherapy cohorts. These findings support personalized de-escalation strategies by identifying biologically indolent tumors in patients with adverse clinical risk factors, potentially reducing overtreatment.

Following this milestone, mdxhealth is advancing its collaboration with Oxford in the UK ProtecT trial, initiating GPS mdx testing in over 1,500 men with long-term outcomes across active surveillance, surgery and radiotherapy arms. This randomized trial aims to establish the assay as the first genomic classifier validated by randomized clinical evidence in prostate cancer management.